Tumor Microenvironment– tag –
-
FDA Clears Clinical Trial for CAR T-Cell Therapy in Advanced Colorectal Cancer, Expanding Solid Tumor Reach
University of Colorado Anschutz USA Overview The U.S. Food and Drug Administration (FDA) has authorized researchers at the University of Colorado Anschutz to conduct a clinical trial for CAR T-cell therapy targeting advanced colorectal c... -
Moffitt Cancer Center’s Dr. Yvonne Chen Proposes Novel Strategies to Overcome Tumor Microenvironment Barriers in Solid Tumors with Logic-Gated CAR T-Cells
Moffitt Cancer Center USA Overview Dr. Yvonne Chen of Moffitt Cancer Center has discussed new strategies to enhance CAR-T cell therapy for solid tumors, focusing on precise targeting with logic-gated CAR-T cells and reprogramming the tum... -
CRDWC 2026 Symposium to Address CAR-T Challenges in Solid Tumors: Focus on Design, Manufacturing, and Safety Strategies
CRDWC 2026 (Cancer Research and Development Conference 2026) Unknown Overview The 2026 Cancer Research and Development Conference will host a symposium dedicated to expanding CAR-T cell therapy from hematological malignancies to solid tu... -
3D Bioprinting Advances Tumor Organoid Modeling and Bone Regeneration Spheroids
PMC - NIH USA Overview 3D bioprinting technology is revolutionizing cancer modeling by enabling the construction of human tumor organoids that accurately recapitulate complex tumor microenvironments for high-throughput drug screening. Co... -
UCSD Advances Next-Gen CAR-T & Gamma Delta T-Cell Therapies for Solid Tumors in Multiple Phase 1 Clinical Trials
UCSD USA Overview UCSD is actively pursuing multiple Phase 1 clinical trials for next-generation cell therapies targeting advanced solid tumors. Featured trials include FT825/ONO-8250, an off-the-shelf HER2 CAR-T, and A2B395, an allogene... -
New CAR-T Engineering Strategies Target Solid Tumor Barriers: Leveraging Real-World Data & Manufacturing Innovations
ecancer International Overview Novel engineering strategies for CAR-T cell therapy against solid tumors are focusing on enhancing T-cell anti-tumor activity and overcoming microenvironmental barriers. Recent clinical results, such as int... -
Xilio Therapeutics Reports Q2 2026 Financial Results, Advances Tumor Microenvironment-Activated Immunotherapy Pipeline with Promising Early Clinical Data
GlobeNewswire USA Overview Xilio Therapeutics released its Q2 2026 financial results, reporting significant pipeline progress for its tumor microenvironment (TME)-activated immunotherapy candidates. Lead programs XTX101, XTX202, and XTX3... -
USC Viterbi Engineers Develop ‘SHIFTERS’ Strategy to Enhance CAR T-Cell Efficacy Against Solid Tumors Using Hypoxia and Focused Ultrasound for Inducible CD19 Expression
Bioengineer.org USA Overview Researchers at the USC Viterbi School of Engineering have developed 'SHIFTERS,' a novel strategy to boost CAR T-cell efficacy against solid tumors. This innovative approach leverages tumor hypoxia and focused... -
iPSC-Derived Microglia-like Cells Reveal Protocol-Specific Transcriptomes and Potent Glioma Phagocytosis, Advancing Brain Tumor Research
bioRxiv USA Overview Human induced pluripotent stem cell (iPSC)-derived microglia-like cells (iMG) are emerging as critical tools for understanding human microglia function and the brain tumor microenvironment. A comprehensive study anal... -
Children’s Hospital of Philadelphia Develops CAR T-Cell Therapy for Pediatric Solid Tumors: First Human Trial Targets PHOX2B-Derived Peptides
Children's Hospital of Philadelphia (CHOP) USA Overview Researchers at Children's Hospital of Philadelphia (CHOP) are leading the development of CAR T-cell therapies for pediatric solid tumors like neuroblastoma. A 'peptide-centric' (PC-...
12